Gal Peter
Graduate Pharmacy Education, Greensboro Area Health Education Center; UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina; Neonatal Pharmacotherapy Fellowship and Neonatal Pharmacology Research Laboratory, Women's Hospital, Moses Cone Health System, Greensboro, North Carolina.
J Pediatr Pharmacol Ther. 2009 Apr;14(2):66-74. doi: 10.5863/1551-6776-14.2.66.
Therapeutic drug monitoring is increasingly giving way to dosing drugs based on population-based pharmacokinetic parameters, even when pharmacokinetic values vary quite a bit in individual patients. Further, drug concentrations are often considered appropriate if they are within a defined therapeutic range, even if the patient response is suboptimal. This lecture discusses the limitations of therapeutic ranges in neonates, and proposes greater emphasis on pharmacodynamic curves to individualize drug therapy. Examples are provided using methylxanthines, indomethacin, antiepileptic drugs and aminoglycosides. The potential to use pharmacokinetic findings to describe physiologic changes and occasionally assist with diagnosis is also discussed.
治疗药物监测正越来越多地被基于群体药代动力学参数的给药方式所取代,即使个体患者的药代动力学值差异很大。此外,药物浓度通常只要在规定的治疗范围内就被认为是合适的,即使患者的反应并不理想。本讲座讨论了新生儿治疗范围的局限性,并建议更加强调药代动力学曲线以实现药物治疗的个体化。文中提供了使用甲基黄嘌呤、吲哚美辛、抗癫痫药物和氨基糖苷类药物的示例。还讨论了利用药代动力学研究结果描述生理变化并偶尔辅助诊断的可能性。